Nek2/7-IN-51

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534622

CAS#: N/A

Description: Nek2/7-IN-51 is a novel ATP-competitive inhibitor of Nek2 and Nek7.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-09-26. Prices are subject to change without notice.

Nek2/7-IN-51 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, SDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 534622
Name: Nek2/7-IN-51
CAS#: N/A
Chemical Formula: C23H33N7O3S
Exact Mass: 487.2366
Molecular Weight: 487.623
Elemental Analysis: C, 56.65; H, 6.82; N, 20.11; O, 9.84; S, 6.57


Synonym: Nek2/7-IN-51

IUPAC/Chemical Name: 3-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)-N-(3-(dimethylamino)propyl)benzenesulfonamide

InChi Key: PEEXIAQHZDNIBT-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H33N7O3S/c1-30(2)13-7-12-26-34(31,32)19-11-6-10-18(14-19)27-23-28-21-20(24-16-25-21)22(29-23)33-15-17-8-4-3-5-9-17/h6,10-11,14,16-17,26H,3-5,7-9,12-13,15H2,1-2H3,(H2,24,25,27,28,29)

SMILES Code: O=S(C1=CC=CC(NC2=NC(OCC3CCCCC3)=C4N=CNC4=N2)=C1)(NCCCN(C)C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 Jul 2;128(7):2877-2893. doi: 10.1172/JCI98765. Epub 2018 Jun 4. PMID: 29863498; PMCID: PMC6026005.

2: Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4. PMID: 28086949; PMCID: PMC5237262.

3: Deng L, Sun J, Chen X, Liu L, Wu D. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019 Jul 18;38(1):316. doi: 10.1186/s13046-019-1311-z. PMID: 31319849; PMCID: PMC6639974.

4: Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001. PMID: 23328480; PMCID: PMC3954609.

5: Cheng Y, Chen X, Ye L, Zhang Y, Liang J, Liu W, Zhou B, Zheng S, Huang Y, Chen G, Deng Y, Zhang Q, Yang Y. The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study. Cell Physiol Biochem. 2018;51(6):2746-2759. doi: 10.1159/000495966. Epub 2018 Dec 12. PMID: 30562736.

6: Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest. 2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24. PMID: 28737508; PMCID: PMC5531394.

7: Ren Q, Li B, Liu M, Hu Z, Wang Y. Prognostic value of NEK2 overexpression in digestive system cancers: a meta-analysis and systematic review. Onco Targets Ther. 2018 Oct 18;11:7169-7178. doi: 10.2147/OTT.S169911. PMID: 30425509; PMCID: PMC6203090.

8: Lu H, Yao B, Wen X, Jia B. FBXW7 circular RNA regulates proliferation, migration and invasion of colorectal carcinoma through NEK2, mTOR, and PTEN signaling pathways in vitro and in vivo. BMC Cancer. 2019 Sep 13;19(1):918. doi: 10.1186/s12885-019-6028-z. PMID: 31519156; PMCID: PMC6744671.

9: Li Y, Chen L, Feng L, Zhu M, Shen Q, Fang Y, Liu X, Zhang X. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3. Am J Cancer Res. 2019 Nov 1;9(11):2364-2378. PMID: 31815040; PMCID: PMC6895449.

10: Wang X, Chen K, Liu H, Huang Z, Chen X, Yin L. Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis. Biosci Rep. 2019 Jan 18;39(1):BSR20180618. doi: 10.1042/BSR20180618. PMID: 30578380; PMCID: PMC6341124.